Advanced Neuroendocrine Tumors | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Cancers known as neuroendocrine tumors develop from specialized cells known as neuroendocrine cells. Similar to neurons and cells that make hormones, neuroendocrine cells have these characteristics. Anywhere in the body can develop neuroendocrine tumors, which are uncommon. Only 0.05% of malignant tumors are neuroendocrine tumors. Depending on where the appendix is located, its incidence is around 2/100,000 and it primarily affects women under 50. The only treatment option and cure available to NET patients is surgery. Unless the patient's general condition or other contraindications preclude surgery, medical care should always be taken into consideration in addition to surgery.

Description

Cancers that develop from specialized cells known as neuroendocrine cells are known as neuroendocrine tumors. Neuronal and hormone-producing cells share characteristics with neuroendocrine cells. Neuroendocrine tumors can develop anywhere in the body and are uncommon. Most neuroendocrine tumors develop in the pancreas, lung, cecum, small intestine, and rectum. Neuroendocrine tumors come in a variety of forms. Some people develop more quickly than others. Functional neuroendocrine tumors are neuroendocrine tumors that overproduce hormone. Others (dysfunctional neuroendocrine tumors) either do not secrete hormones at all or not in quantities sufficient to produce symptoms. The type and location of the tumor, whether it produces an excessive number of hormones, how severe it is, and whether it has spread to other body parts are all factors in the diagnosis and treatment of neuroendocrine tumors.

Advanced Neuroendocrine Tumors (Epidemiology)

Of all malignant tumors, neuroendocrine tumors make up just 0.05%. Depending on where the appendix is, it has an incidence of about 2/100,000 and mostly affects women under 50. The lung (22-27%) and gastrointestinal tract (62-67%) are the two main primary sites. 12-22% of cases are present with metastatic disease. The incidence has increased over the past few decades. This might result from increased awareness, better diagnostic equipment, or a definitional change. Although clustering within families and association with the multiple endocrine neoplasia type 1 syndrome are known, most neuroendocrine tumors are sporadic in nature. Additionally, although the numbers are small, there has been information about an increased risk of secondary cancers. Stage primarily affects the 5-year survival rate: local disease accounts for 93%, regional disease for 74%, and metastatic disease for 19%. Since 1992, when octreotide treatment became widely accessible in The Netherlands, survival rates for patients with metastatic disease have risen.

Advanced Neuroendocrine Tumors -Current Market Size & Forecast Trends

The market for advanced neuroendocrine tumors (NETs) is expected to grow significantly, with an estimated value of about USD 2.04 billion in 2024, projected to reach around USD 5.62 billion by 2037, reflecting a compound annual growth rate (CAGR) of 8.1%. This growth is driven by the increasing incidence of NETs, advancements in treatments like somatostatin analogs and targeted therapies, and greater awareness of the disease. As new therapies and diagnostic technologies continue to emerge, the market for advanced neuroendocrine tumors is well-positioned for substantial expansion through 2035.

For patients with NET, surgery is still the only treatment option with a cure. Unless the patient's general health or other factors make surgery impossible, medical care should always be considered in addition to surgery. Surgery has been used in metastatic disease to enhance hormone-related symptoms and quality of life, decrease tumor size, stop further local and systemic effects, and even enhance survival in some tumor types, particularly colon cancer. Even after drug therapy has significantly decreased the number of tumors, surgery can be used to extend disease-free periods to maximize treatment effect, even though a recent study suggests that the majority of these patients will eventually relapse. The detection of hidden lesions and tissue networks has been significantly aided by the development of nuclear techniques such as PET imaging and SS isotope scintigraphy. A multimodal approach is necessary for the effective treatment of metastatic networks with the goals of symptom management, halting the progression of the tumor, and ultimately, hopefully, cure, though the latter is virtually unattainable. SS analogs can help patients get ready for surgery by reducing the symptoms that are frequently brought on by functional GEP tumors. Additionally, these patients can safely undergo potentially curative surgery thanks to the best preoperative symptom control brought on by the hypersecretion of catecholamines or other metabolically active substances resulting from pheochromocytomas. As the only available treatment, radical tumor surgery is a requirement. Recently, surgical approaches have become more aggressive, including wide metastasis excision, liver metastasis resection, use of adjuvant chemotherapy, or focal liver resection. It was done to embolize the hepatic artery. If surgical intervention is not an option, prognostic factors and current classification schemes should be used to guide treatment. Well-differentiated, slow-growing GEP tumors should be treated with SS or INF-analogs alone or in combination, though we frequently use SS analogues earlier in the course of the treatment rather than INF. For poorly differentiated and advanced GEP tumors, chemotherapy should be taken into consideration. When conventional or biologic therapy fails, radionuclide therapy, such as 131I-MIBG for pheochromocytic tumors and radioactive SS isotope therapy for other tissues, may be used to eradicate microscopic disease that is still present after surgery or to demonstrate diagnostic screening. evaluate tumor uptake. Patients with advanced disease and GEP tumors, as well as those with metastatic pheochromocytoma and MTC despite biological therapy or radioactive SS isotope therapy, may instead receive chemotherapy. Nevertheless, when employing this strategy, it is important to consider the patient's activity level and resting state, tumor growth rate, and side effects.

Report Highlights

Advanced Neuroendocrine Tumors - Current Market Trends

Advanced Neuroendocrine Tumors - Current & Forecasted Cases across the G8 Countries

Advanced Neuroendocrine Tumors - Market Opportunities and Sales Potential for Agents

Advanced Neuroendocrine Tumors - Patient-based Market Forecast to 2035

Advanced Neuroendocrine Tumors - Untapped Business Opportunities

Advanced Neuroendocrine Tumors - Product Positioning Vis-a-vis Competitors' Products

Advanced Neuroendocrine Tumors - KOLs Insight